Please login to the form below

Not currently logged in

Peter Chambre joins cancer vaccine biotech Immatics

He replaces Thomas Widmann as chair of the board

Immatics Peter ChambreImmatics Biotechnologies has appointed Peter Chambré as chairman of the board to replace Thomas Widmann, who steps down after eight years in the post.

Chambré holds several chairman positions in the life sciences industry and previously served as CEO of Cambridge Antibody Technology from 2002 until its acquisition by AstraZeneca in 2006.

Paul Higham, CEO of Immatics, said: “I am delighted to welcome Peter as our new chairman. We are approaching a crucial period at Immatics, and Peter's experience and track record in successfully developing biopharmaceutical companies will be invaluable, as we seek to produce a step-change in the treatment of cancer and maximise returns to our investors.”

Chambré joins Tuebingen-based Immatics following the German biotech's recent completion of phase III patient enrollment for a trial of its therapeutic vaccine for renal cancer IMA901.

He said: “Immatics' vaccines, based on the company's highly rational approach to cancer vaccine discovery, have already demonstrated very promising results in clinical trials.

“With IMA901, Immatics' lead multi-peptide based vaccine now in phase III development for renal cancer, and a number of other projects in clinical development, this is an extremely exciting company.”

14th November 2012

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...